Statistical power for MACE and individual secondary endpoints in cardiovascular outcomes trials for type 2 diabetes: a systematic review

Cardiovascular outcomes trials (CVOTs) with novel drugs to treat type 2 diabetes have uniformly chosen the composite “major adverse cardiovascular events (MACE)” as their primary endpoint, but they also report hazard ratios for individual cardiovascular outcomes (myocardial infarction, stroke, cardi...

Descripción completa

Detalles Bibliográficos
Autores principales: Birker, Sebastian, Meier, Juris J., Nauck, Michael A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726861/
https://www.ncbi.nlm.nih.gov/pubmed/36473887
http://dx.doi.org/10.1038/s41598-022-25296-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9726861/
https://www.ncbi.nlm.nih.gov/pubmed/36473887
http://dx.doi.org/10.1038/s41598-022-25296-x

Ejemplares similares